Emerging Invasive Fungal Infections in Critically Ill Patients

Completed

• Conditions: ICU Acquired Weakness; Fungal Infection

• Registration Number: NCT04647539
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Rationale: Beside Candida and Aspergillus, emerging invasive fungal infections (EIFIs) are increasing in intensive care setting and are associated with high morbidity and mortality. However, data are scarce, particularly in ICU settings and for EIFIs other than mucormycosis.

Objectives: to describe epidemiological trends and clinical features of EIFIs in intensive care units (ICU) and to assess their outcome.

Methods: All records of adult patients diagnosed with an EIFI in a medical ICU between 2006 and 2019 were analyzed retrospectively. In-ICU mortality was assessed, then factors associated with mortality were identified. Survival at day-90 was calculated by the Kaplan-Meier method.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-01
• Primary Completion: 2019-12-01
• Status Verified: 2020-11
• Study Completion: 2020-11-23
• Study First Submitted: 2020-11-23
• Study First Submitted QC: 2020-11-23
• Last Update Submitted: 2020-11-23
• Study First Posted: 2020-12-01
• Last Update Posted: 2020-12-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality	at ICU admission	mortality

Secondary Outcome Measures

Name	Time	Method
Mucormycosis	at ICU admission	Mucormycosis

Trial Locations

Locations (1)

Uhmontpellier; 🇫🇷 Montpellier, France